STARD and CONSORT: time for reflection

Excerpt

Our community has always believed that Nuclear Medicine deserves a special place in the non-invasive assessment of the extent and severity of a variety of diseases, and cancer in particular. The ability to characterise the metabolic and functional status of a mass was the dream of our forefathers in the field, who also believed that we would not only deliver sensitive diagnostic procedures but also develop new treatments based on magic bullets. This dream is far from over, and at times we wake up to the exciting reality of new diagnostic ligand-based procedures (FDG PET/CT is one powerful example) and new radioligand-based treatments (such as yttrium-90 or iodine-131 labelled monoclonal antibodies for lymphoma). …